| 001 | 177407 | ||
| 005 | 20240229143542.0 | ||
| 024 | 7 | _ | |2 doi |a 10.1007/s00259-021-05602-x |
| 024 | 7 | _ | |2 pmid |a pmid:34773163 |
| 024 | 7 | _ | |2 ISSN |a 0340-6997 |
| 024 | 7 | _ | |2 ISSN |a 1432-105X |
| 024 | 7 | _ | |2 ISSN |a 1619-7070 |
| 024 | 7 | _ | |2 ISSN |a 1619-7089 |
| 037 | _ | _ | |a DKFZ-2021-02499 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |0 P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9 |a Rühle, Alexander |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation-results from a prospective pilot trial. |
| 260 | _ | _ | |a Heidelberg [u.a.] |b Springer-Verl. |c 2022 |
| 336 | 7 | _ | |2 DRIVER |a article |
| 336 | 7 | _ | |2 DataCite |a Output Types/Journal article |
| 336 | 7 | _ | |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |a Journal Article |b journal |m journal |s 1675243256_7227 |
| 336 | 7 | _ | |2 BibTeX |a ARTICLE |
| 336 | 7 | _ | |2 ORCID |a JOURNAL_ARTICLE |
| 336 | 7 | _ | |0 0 |2 EndNote |a Journal Article |
| 500 | _ | _ | |a #EA:E055#LA:E055# / 2022 Apr;49(5):1650-1660 |
| 520 | _ | _ | |a Intratumoral hypoxia increases resistance of head-and-neck squamous cell carcinoma (HNSCC) to radiotherapy. [18F]FMISO PET imaging enables noninvasive hypoxia monitoring, though requiring complex logistical efforts. We investigated the role of plasma interleukin-6 (IL-6) as potential surrogate parameter for intratumoral hypoxia in HNSCC using [18F]FMISO PET/CT as reference.Within a prospective trial, serial blood samples of 27 HNSCC patients undergoing definitive chemoradiation were collected to analyze plasma IL-6 levels. Intratumoral hypoxia was assessed in treatment weeks 0, 2, and 5 using [18F]FMISO PET/CT imaging. The association between PET-based hypoxia and IL-6 was examined using Pearson's correlation and multiple regression analyses, and the diagnostic power of IL-6 for tumor hypoxia response prediction was determined with receiver-operating characteristic analyses.Mean IL-6 concentrations were 15.1, 19.6, and 31.0 pg/mL at baseline, week 2 and week 5, respectively. Smoking (p=0.050) and reduced performance status (p=0.011) resulted in higher IL-6 levels, whereas tumor (p=0.427) and nodal stages (p=0.334), tumor localization (p=0.439), and HPV status (p=0.294) had no influence. IL-6 levels strongly correlated with the intratumoral hypoxic subvolume during treatment (baseline: r=0.775, p<0.001; week 2: r=0.553, p=0.007; week 5: r=0.734, p<0.001). IL-6 levels in week 2 were higher in patients with absent early tumor hypoxia response (p=0.016) and predicted early hypoxia response (AUC=0.822, p=0.031). Increased IL-6 levels at week 5 resulted in a trend towards reduced progression-free survival (p=0.078) and overall survival (p=0.013).Plasma IL-6 is a promising surrogate marker for tumor hypoxia dynamics in HNSCC patients and may facilitate hypoxia-directed personalized radiotherapy concepts.The prospective trial was registered in the German Clinical Trial Register (DRKS00003830). Registered 20 August 2015. |
| 536 | _ | _ | |0 G:(DE-HGF)POF4-315 |a 315 - Bildgebung und Radioonkologie (POF4-315) |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 650 | _ | 7 | |2 Other |a Biomarker |
| 650 | _ | 7 | |2 Other |a FMISO-PET |
| 650 | _ | 7 | |2 Other |a Head-and-neck cancer |
| 650 | _ | 7 | |2 Other |a Hypoxia |
| 650 | _ | 7 | |2 Other |a Interleukin-6 |
| 650 | _ | 7 | |2 Other |a Radiotherapy |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Wiedenmann, Nicole |b 1 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Fennell, Jamina T |b 2 |
| 700 | 1 | _ | |a Mix, Michael |b 3 |
| 700 | 1 | _ | |a Ruf, Juri |b 4 |
| 700 | 1 | _ | |0 P:(DE-He78)75b4c256a6de824414938cf2aaeff88e |a Stoian, Raluca |b 5 |u dkfz |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Thomsen, Andreas R |b 6 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Vaupel, Peter |b 7 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Baltas, Dimos |b 8 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Grosu, Anca-L |b 9 |
| 700 | 1 | _ | |0 P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd |a Nicolay, Nils |b 10 |e Last author |u dkfz |
| 773 | _ | _ | |0 PERI:(DE-600)2098375-X |a 10.1007/s00259-021-05602-x |n 5 |p 1650-1660 |t European journal of nuclear medicine and molecular imaging |v 49 |x 1619-7089 |y 2022 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:177407 |p VDB |
| 910 | 1 | _ | |0 I:(DE-588b)2036810-0 |6 P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9 |a Deutsches Krebsforschungszentrum |b 0 |k DKFZ |
| 910 | 1 | _ | |0 I:(DE-588b)2036810-0 |6 P:(DE-HGF)0 |a Deutsches Krebsforschungszentrum |b 1 |k DKFZ |
| 910 | 1 | _ | |0 I:(DE-588b)2036810-0 |6 P:(DE-HGF)0 |a Deutsches Krebsforschungszentrum |b 2 |k DKFZ |
| 910 | 1 | _ | |0 I:(DE-588b)2036810-0 |6 P:(DE-He78)75b4c256a6de824414938cf2aaeff88e |a Deutsches Krebsforschungszentrum |b 5 |k DKFZ |
| 910 | 1 | _ | |0 I:(DE-588b)2036810-0 |6 P:(DE-HGF)0 |a Deutsches Krebsforschungszentrum |b 6 |k DKFZ |
| 910 | 1 | _ | |0 I:(DE-588b)2036810-0 |6 P:(DE-HGF)0 |a Deutsches Krebsforschungszentrum |b 7 |k DKFZ |
| 910 | 1 | _ | |0 I:(DE-588b)2036810-0 |6 P:(DE-HGF)0 |a Deutsches Krebsforschungszentrum |b 8 |k DKFZ |
| 910 | 1 | _ | |0 I:(DE-588b)2036810-0 |6 P:(DE-HGF)0 |a Deutsches Krebsforschungszentrum |b 9 |k DKFZ |
| 910 | 1 | _ | |0 I:(DE-588b)2036810-0 |6 P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd |a Deutsches Krebsforschungszentrum |b 10 |k DKFZ |
| 913 | 1 | _ | |0 G:(DE-HGF)POF4-315 |1 G:(DE-HGF)POF4-310 |2 G:(DE-HGF)POF4-300 |3 G:(DE-HGF)POF4 |4 G:(DE-HGF)POF |a DE-HGF |b Gesundheit |l Krebsforschung |v Bildgebung und Radioonkologie |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2021-02-02 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-02 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-02 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NUCL MED MOL I : 2021 |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-23 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-23 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b EUR J NUCL MED MOL I : 2021 |d 2022-11-23 |
| 920 | 1 | _ | |0 I:(DE-He78)E055-20160331 |k E055 |l E055 KKE Molekulare Radioonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)FR01-20160331 |k FR01 |l DKTK FR zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E055-20160331 |
| 980 | _ | _ | |a I:(DE-He78)FR01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::